Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 7 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
GeneCure Consulting from Bierbeek, company number BE0667508666, closed financial year 2025 with a result of € -29,178 after tax. For that financial year GeneCure Consulting recorded a gross margin of € 1,447 and equity of € -62,468. Compared with financial year 2024, the result moved from € -15,750 to € -29,178. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ -62,468
▼ € 29,178 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -29,178
▼ 85 % more loss than in 2024
Profit after tax over the fiscal year.
€ 376
▼ 84% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -68,668.
People and assets in 2025
€ 68,227
▲ € 63,800 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 124,830
▲ 238% vs 2024
€ 12,294 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.
€ 8,154
▼ 1% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 534
▲ 63% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 4,693 | € -1,328 | € -378 | € 1,447 | ▲ € 1,825 |
| Profit after taxes | € -12,997 | € -17,554 | € -15,750 | € -29,178 | ▼ € 13,428 |
| Equity | € 14 | € -17,540 | € -33,290 | € -62,468 | ▼ € 29,178 |
| Total debts | € 93,498 | € 97,785 | € 107,733 | € 200,756 | ▲ 86% |
| Cash | € 1,798 | € 1,550 | € 2,283 | € 376 | ▼ 84% |
| Land & buildings | € 73,895 | € 63,754 | € 53,613 | € 44,785 | ▼ 16% |
| Retained profit | € -6,186 | € -23,740 | € -39,490 | € -68,668 | ▼ € 29,178 |
| Bank debt | € 65,587 | € 48,709 | € 36,886 | € 124,830 | ▲ 238% |
| Balance sheet total | € 93,512 | € 80,245 | € 74,443 | € 138,288 | ▲ 86% |
Key figures of GeneCure Consulting, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to GeneCure Consulting?
What happened at GeneCure Consulting in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 29,178. filed late Source: NBB ↗
- New establishment in Bierbeek. KBO
- Start of the company according to the CBE. KBO
- THIERRY VANDENDRIESSCHE became a director. NBB
- LAY KHIM CHUAH became a director. NBB
In short
From € 12,997 loss in 2022 to € 29,178 loss in 2025.
Paid € 788 in corporate taxes since 2022.
Management
Behind GeneCure Consulting are THIERRY VANDENDRIESSCHE and LAY KHIM CHUAH.
Directors
According to the 2025 annual accounts
THIERRY VANDENDRIESSCHE
Director
since 2016
LAY KHIM CHUAH
Director
since 2016
Establishments
Establishment units
Physical locations of this company
Tiensesteenweg 250
3360 Bierbeek
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0667.508.666
- VAT number
- BE 0667.508.666
- Registered office
- Tiensesteenweg 250, 3360 Bierbeek
- Names & denominations
- GeneCure Consulting
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 December 2016
- Peppol
- Active · Active since 9 Jan 2026
- Activities · NACE
Organisatie van congressen en beurzen
Speur- en ontwikkelingswerk op biotechnologisch gebied